IN 005
Alternative Names: IN-005Latest Information Update: 22 Mar 2024
At a glance
- Originator Inhalon Biopharma
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Influenza virus infections
Most Recent Events
- 22 Mar 2024 Inhalon Biopharma plans clinical trials in Influenza virus infections (Inhalation)
- 20 Nov 2023 Inhalon Biopharma has patent protection for muco-trapping technology in USA, Europe and throughout the world (Inhalon Biopharma website, November 2023)
- 20 Nov 2023 Early research in Influenza virus infections in USA (Parenteral) (Inhalon Biopharma pipeline, November 2023)